Cerevel Therapeutics sold the stake/assets to AbbVie as part of a acquisition on 2023-12-06.
Deal value was 87000000000 (source: Extracted) Seller position: 100% acquisition; Sector: Healthcare; Location: USA.
On the seller side, Latham & Watkins advised, led by Charles Ruck, Daniel Rees, Greg Rodgers.
Generated by AI, original source from - Data is in progress
Found it useful? Spread the word.
Kirkland & Ellis advises AbbVie on its $8.7 billion acquisition of Cerevel Therapeutics, with Latham & Watkins advising Cerevel Therapeutics. | The Sponsor - The Sponsor
